Design and evaluation of a sustained release gastroretentive dosage form of captopril: A technical note

AAPS PharmSciTech

Volumn 9, Issue 3, 2008, Pages 836-839

  Patel, P ^a   Dand, N ^a   Somwanshi, A ^a   Kadam, V J ^a   Hirlekar, R S ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Factorial design; Floating drug delivery; HPMC

Indexed keywords

CAPTOPRIL;

ARTICLE; DRUG DOSAGE FORM; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MOISTURE; OSMOLARITY; PH; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

CAPTOPRIL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; GASTROINTESTINAL AGENTS;

EID: 57149123032     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9120-2     Document Type: Article

References (15)

1. P. R. Sheth, and J. L. Tossounian. The hydrodynamic balanced system (HBS): A novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10: 339 (1984).
2. Y. E. Chien. Potential developments, new approaches in oral controlled release drug delivery systems. Drug Dev. Ind. Pharm. 9: 486-488 (1993).
3. A. A. Deshpande, C. T. Rhodes, N. H. Shah, and A. W. Malick. Controlled release drug delivery systems for prolonged gastric residence: An overview. Drug Dev. Ind. Pharm. 22: 531-539 (1996).
4. N. Uzdemir, S. Ordu, and Y. Ozkan. Studies of floating dosage forms of furosemide: In vitro and in vivo evaluation of bilayer tablet formulations. Drug Dev. Ind. Pharm. 26: 857-866 (2000).
5. H. M. Ingani, J. Timmermans, and A. J. Moes. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit. Int. J. Pharm. 35: 157-164 (1987).
6. C. Dollery. Therapeutics Drugs, Churchill Livingstone, New York, 1999, pp. 38-43.
7. N. H. Anaizi, and C. Swenson. Instability of CAP solution. Am. J. Hosp. Pharm. 50: 486-488 (1993).
8. M. Rosa, H. Zia, and T. Rhodes. Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int. J. Pharm. 105: 65-70 (1994).
9. H. Ansel and M. Stoklosa (eds) Pharmaceutical Calculations, 11th edn, Lippincott, Williams and Wilkins, Baltimore, MD, 2001, pp. 178-180.
10. A. K. Srivastava, S. Wadhwa, D. Ridhurkar, and B. Mishra. Oral sustained delivery of atenolol from floating matrix tablets formulation and in vitro evaluation. Drug Dev. Ind. Pharm. 31: 367-374 (2005).
11. Indian Pharmacopoeia Commission. Indian Pharmacopoeia, vol. 1, Controller of Publication, Delhi, 1996, p 135
12. A. A. Chivate, S. S. Poddar, S. Abdul, and G. Savant. Evaluation of Sterculia foetida gum as controlled release excipient. AAPSPharmSciTech. 9: 197-204 (2008).
13. S. Baumgartner, J. Smid-Korber, F. Vreces, and J. Kristl. Physical and technological parameters influencing floating properties of matrix tablets based on cellulose ethers. STP Pharma. Sciences. 8: 182-187 (1998).
14. J. Timmermans, and A. J. Moes. How well do floating dosage forms float. Int. J. Pharm. 62: 207-216 (1990).
15. L. S. C. Wan, P. W. S. Heng, and L. F. Wong. Matrix swelling: A simple model describing extent of swelling of HPMC matrices. Int. J. Pharm. 116: 159-168 (1995).